Skip to main content

Table 1 Summary of TCD 50 values and enhancement ratios (ER) for different treatments

From: BAY 87–2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts

Experimental arm

TCD50[95% CI] (Gy) (p-value vs. control)

ER

1) RT

122.7 [108;149] -

-

2) BAY-87-2243 + RT

99.7 [88;117] (0.037)

1.23

3) BAY-87-2243 + RT/BAY-87-2243

114.3 [103;132] (0.4)

1.07

4) RCT

99.5 [83;124] -

-

5) RCT/BAY-87-2243

107.2 [97;123] (0.5)

0.93

6) BAY-87-2243 + RCT/BAY-87-2243

113.6 [97; 145] (0.3)

0.88

  1. P-value <0.05 indicates significant differences between experimental treatment and respective control (RT or RCT).
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us